Neurocrine Biosciences, Inc. (NBIX) News

Neurocrine Biosciences, Inc. (NBIX): $134.57

0.50 (+0.37%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

A

Add NBIX to Watchlist
Sign Up

Filter NBIX News Items

NBIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NBIX News Highlights

  • NBIX's 30 day story count now stands at 9.
  • Over the past 24 days, the trend for NBIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about NBIX are DRUG and KNSA.

Latest NBIX News From Around the Web

Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

3 Stocks at the Forefront of Medical Innovation

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

Gabriel Osorio-Mazzilli on InvestorPlace | December 26, 2023

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […]

Yahoo | December 26, 2023

Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?

Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Yahoo | December 26, 2023

Neurocrine Biosciences' (NASDAQ:NBIX) five-year earnings growth trails the 12% YoY shareholder returns

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...

Yahoo | December 25, 2023

Here’s Why Neurocrine Biosciences (NBIX) Rose in Q3

Harding Loevner, an asset management company, released its “Global Small Companies Equity Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here. Global small caps fell sharply in the third quarter. Japan was the weakest region, although returns in healthcare were good and industrials detracted. The strategy returned -5.36% (net) compared to […]

Yahoo | December 20, 2023

Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NASDAQ:NBIX), a prominent player in the biopharmaceutical industry, has recently witnessed a significant insider transaction.

Yahoo | December 16, 2023

The 3 Most Undervalued Biotech Stocks to Buy in December

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Gabriel Osorio-Mazzilli on InvestorPlace | December 15, 2023

Insider Sell Alert: Chief Legal Officer Darin Lippoldt Sells Shares of Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NASDAQ:NBIX), a prominent player in the biopharmaceutical industry, has recently witnessed a significant insider sell by its Chief Legal Officer, Darin Lippoldt.

Yahoo | December 10, 2023

Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for crinecerfont in congenital adrenal hyperplasia. The Company also provided updates on its R&D portfolio and strategy at its Analyst Day, held in New York.

Yahoo | December 5, 2023

Insider Sell Alert: Chief Scientific Officer Jude Onyia Sells Shares of Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NASDAQ:NBIX), a prominent player in the biopharmaceutical industry, has recently witnessed a significant insider sell event.

Yahoo | December 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!